Back to top
more

Flex Pharma, Inc. (FLKS)

(Delayed Data from NSDQ)

$0.46 USD

0.46
204,419

-0.02 (-3.26%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Salarius Pharmaceuticals, Inc. [FLKS]

Reports for Purchase

Showing records 1 - 20 ( 85 total )

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for FLKS

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

07/22/2018

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

06/29/2018

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/29/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/29/2018

Company Report

Pages: 6

What We Talk About When We Talk About Flex

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/03/2018

Company Report

Pages: 5

Positive Signals Lend Support to FLX-787?s Utility in Multiple Sclerosis Spasticity

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/26/2018

Company Report

Pages: 4

MS Data Suggests New Value Opportunity; Reiterate Buy and $12 PT

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

03/26/2018

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/20/2018

Industry Report

Pages: 6

Healthcare - FLT3, Out of the Box

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/08/2018

Company Report

Pages: 5

Upcoming Data Should Mark Official Transition of FLKS to a Pharma Company; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/08/2018

Company Report

Pages: 6

Awaiting Exploratory MS Readout in March

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/08/2018

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

01/03/2018

Company Report

Pages: 11

New Year, New Flex; Resuming with Buy and $12 PT

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

01/03/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/29/2017

Company Report

Pages: 4

We are placing shares of FLKS Under Review, and transferring coverage to Jotin Marango, M.D., Ph.D.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/29/2017

Industry Report

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/07/2017

Company Report

Pages: 12

Small Trial, But Strong Efficacy Signals from FLX-787 in ALS

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/07/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

11/07/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Salarius Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/07/2017

Company Report

Pages: 12

Small Trial, But Strong Efficacy Signals from FLX-787 in ALS

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party
// eof